Literature DB >> 12546236

An outbreak of pneumococcal pneumonia among military personnel at high risk: control by low-dose azithromycin postexposure chemoprophylaxis.

Jose L Sanchez1, Stephen C Craig, Shellie Kolavic, Deborah Hastings, Bryan J Alsip, Gregory C Gray, Marie K Hudspeth, Margaret A K Ryan.   

Abstract

In the winter of 1998-1999 an outbreak of pneumococcal pneumonia occurred among Ranger students undergoing high-intensity training. Thirty pneumonia cases (attack rate = 12.6%) were identified among a group of 239 students. Eighteen students were hospitalized; Streptococcus pneumoniae-positive cultures were detected in 11 (61.1%) of these 18 hospitalized cases. Pneumococci were also identified in throat swabs of 30 (13.6%) of 221 nonhospitalized students surveyed. Serum antipneumolysin seroconversions were detected in 30 (18.3%) of 164 students tested. An association between development of serum antipneumolysin antibody and pneumococcal pharyngeal carriage/colonization was found. Of 30 seroconverters, eight (26.7%) had S. pneumoniae-positive cultures compared with only 17 (12.7%) of 134 nonseroconverters (relative risks = 2.02, 95% confidence interval = 1.02-4.02, p = 0.05). The outbreak was controlled by administrating lowdose, oral azithromycin prophylaxis (250 mg weekly for 2 weeks) and was associated with a 69% reduction in pneumococcal carriage and a 94% reduction in pneumonia rates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12546236

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  8 in total

1.  Outbreak control of community acquired pneumonia in a large military training institution.

Authors:  Vani Suryam; V K Bhatti; Aniket Kulkarni; A Mahen; Velu Nair
Journal:  Med J Armed Forces India       Date:  2014-11-22

2.  Outbreak of Pneumococcal Pneumonia among Military Recruits.

Authors:  A Banerjee; A T Kalghatgi; G S Saiprasad; A Nagendra; B N Panda; S K Dham; A Mahen; K D Menon; M A Khan
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

4.  Outbreak of pneumonia in the setting of fatal pneumococcal meningitis among US Army trainees: potential role of Chlamydia pneumoniae infection.

Authors:  Fatimah S Dawood; John F Ambrose; Bruce P Russell; Anthony W Hawksworth; Jonas M Winchell; Nina Glass; Kathleen Thurman; Michele A Soltis; Erin McDonough; Agnes K Warner; Emily Weston; Nakia S Clemmons; Jennifer Rosen; Stephanie L Mitchell; Dennis J Faix; Patrick J Blair; Matthew R Moore; John Lowery
Journal:  BMC Infect Dis       Date:  2011-06-02       Impact factor: 3.090

5.  Community-based outbreaks in vulnerable populations of invasive infections caused by Streptococcus pneumoniae serotypes 5 and 8 in Calgary, Canada.

Authors:  Otto G Vanderkooi; Deirdre L Church; Judy MacDonald; Franziska Zucol; James D Kellner
Journal:  PLoS One       Date:  2011-12-27       Impact factor: 3.240

Review 6.  Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review.

Authors:  Paul N Zivich; John D Grabenstein; Sylvia I Becker-Dreps; David J Weber
Journal:  Pneumonia (Nathan)       Date:  2018-11-05

Review 7.  Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness.

Authors:  John F Brundage
Journal:  Lancet Infect Dis       Date:  2006-05       Impact factor: 25.071

8.  Control of Streptococcus pneumoniae serotype 5 epidemic of severe pneumonia among young army recruits by mass antibiotic treatment and vaccination.

Authors:  Ran D Balicer; Salman Zarka; Hagai Levine; Eyal Klement; Tamar Sela; Nurith Porat; Nachman Ash; Ron Dagan
Journal:  Vaccine       Date:  2010-08-02       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.